JP2020528750A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020528750A5 JP2020528750A5 JP2020503984A JP2020503984A JP2020528750A5 JP 2020528750 A5 JP2020528750 A5 JP 2020528750A5 JP 2020503984 A JP2020503984 A JP 2020503984A JP 2020503984 A JP2020503984 A JP 2020503984A JP 2020528750 A5 JP2020528750 A5 JP 2020528750A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- pharmaceutical composition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023095262A JP2023113893A (ja) | 2017-07-27 | 2023-06-09 | 抗ｃｔｌａ－４抗体およびその使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762537753P | 2017-07-27 | 2017-07-27 | |
| US62/537,753 | 2017-07-27 | ||
| US201762588853P | 2017-11-20 | 2017-11-20 | |
| US62/588,853 | 2017-11-20 | ||
| US201862645284P | 2018-03-20 | 2018-03-20 | |
| US62/645,284 | 2018-03-20 | ||
| US201862685599P | 2018-06-15 | 2018-06-15 | |
| US62/685,599 | 2018-06-15 | ||
| PCT/US2018/043936 WO2019023482A1 (en) | 2017-07-27 | 2018-07-26 | ANTI-CTLA-4 ANTIBODIES AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023095262A Division JP2023113893A (ja) | 2017-07-27 | 2023-06-09 | 抗ｃｔｌａ－４抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020528750A JP2020528750A (ja) | 2020-10-01 |
| JP2020528750A5 true JP2020528750A5 (enExample) | 2021-08-26 |
| JP7296363B2 JP7296363B2 (ja) | 2023-06-22 |
Family
ID=63165545
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503984A Active JP7296363B2 (ja) | 2017-07-27 | 2018-07-26 | 抗ｃｔｌａ－４抗体およびその使用 |
| JP2023095262A Pending JP2023113893A (ja) | 2017-07-27 | 2023-06-09 | 抗ｃｔｌａ－４抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023095262A Pending JP2023113893A (ja) | 2017-07-27 | 2023-06-09 | 抗ｃｔｌａ－４抗体およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10844137B2 (enExample) |
| EP (1) | EP3658585A1 (enExample) |
| JP (2) | JP7296363B2 (enExample) |
| KR (1) | KR102710122B1 (enExample) |
| CN (1) | CN111133004B (enExample) |
| AU (1) | AU2018307675B2 (enExample) |
| BR (1) | BR112020001266A2 (enExample) |
| CL (1) | CL2020000216A1 (enExample) |
| CO (1) | CO2020000438A2 (enExample) |
| IL (1) | IL271882B2 (enExample) |
| MA (1) | MA49687A (enExample) |
| MY (1) | MY202870A (enExample) |
| PH (1) | PH12020500078A1 (enExample) |
| SG (1) | SG11202000366WA (enExample) |
| TW (1) | TWI799432B (enExample) |
| WO (1) | WO2019023482A1 (enExample) |
| ZA (1) | ZA202000113B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11013802B2 (en) | 2016-12-07 | 2021-05-25 | Agenus Inc. | Anti-CTLA-4 antibodies and methods of use thereof |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| TWI850282B (zh) | 2018-11-27 | 2024-08-01 | 香港商弘年發展有限公司 | 用於治療癌症之質體建構體和使用方法 |
| EP3898677A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/il-7 molecule |
| IL316757A (en) | 2018-12-27 | 2025-01-01 | Gigagen Inc | Anti-CTLA-4 binding proteins and methods of using them |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| SG11202109003QA (en) * | 2019-03-06 | 2021-09-29 | Regeneron Pharma | Il-4/il-13 pathway inhibitors for enhanced efficacy in treating cancer |
| CN113631189A (zh) | 2019-03-13 | 2021-11-09 | 默沙东公司 | 包含ctla-4和pd-1封闭剂的抗癌联合治疗 |
| CN115942973A (zh) | 2019-11-08 | 2023-04-07 | 百时美施贵宝公司 | 用于黑色素瘤的lag-3拮抗剂疗法 |
| WO2021122866A1 (en) | 2019-12-17 | 2021-06-24 | Ose Immunotherapeutics | Bifunctional molecules comprising an il-7 variant |
| CA3162311A1 (en) * | 2019-12-20 | 2021-06-24 | Philip E. Brandish | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
| JP2023524639A (ja) | 2020-04-22 | 2023-06-13 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 患者特異的免疫療法用細胞の製造調整システム及び調整方法 |
| AU2021299338A1 (en) * | 2020-07-02 | 2023-02-23 | Gigagen, Inc. | Anti-CTLA-4 binding proteins and methods of use thereof |
| IL299152A (en) * | 2020-07-08 | 2023-02-01 | Regeneron Pharma | Stabilized formulations that include antibodies against CTLA-4 |
| US20230372397A1 (en) | 2020-10-06 | 2023-11-23 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| CN116323922A (zh) * | 2020-12-17 | 2023-06-23 | 南京蓬勃生物科技有限公司 | 筛选靶向CD47-SIRPα免疫检查点的候选药物的方法和试剂盒 |
| KR20240032711A (ko) | 2021-03-25 | 2024-03-12 | 이오반스 바이오테라퓨틱스, 인크. | T-세포 공배양 효능 검정 및 세포 치료제와 함께 사용하기 위한 방법 및 조성물 |
| CA3213917A1 (en) | 2021-04-09 | 2022-10-13 | Nicolas Poirier | New scaffold for bifunctional molecules with improved properties |
| WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| EP4422685A4 (en) * | 2021-10-29 | 2025-12-03 | Oncoc4 Inc | ANTI-CTLA-4 ANTIBODY DOSING SCHEMES |
| IL312813A (en) | 2021-11-24 | 2024-07-01 | Regeneron Pharma | Methods for treating cancer using bispecific antibodies against CD3 and MUC16 and antibodies against CTLA-4 |
| CA3248034A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | METHODS FOR EXPANSION OF TIL CELLS BY MEANS OF SPECIFIC CYTOKINE COMBINATIONS AND/OR AKT INHIBITOR TREATMENT |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| JP2025525886A (ja) | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| KR20250122544A (ko) | 2022-11-21 | 2025-08-13 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 확장을 위한 2차원 공정 및 이를 통한 요법 |
| EP4687990A1 (en) | 2023-03-30 | 2026-02-11 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| CN121152808A (zh) * | 2023-06-16 | 2025-12-16 | 嘉和生物药业有限公司 | 抗ccr8抗体和抗ccr8/ctla4双特异性抗体 |
| WO2025140478A1 (zh) * | 2023-12-29 | 2025-07-03 | 百奥泰生物制药股份有限公司 | 抗pd-l1/cd47双特异抗体在联合用药中的应用 |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2112166T3 (en) * | 1998-12-23 | 2019-02-04 | Pfizer | Human monoclonal antibodies to CTLA-4 |
| US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| RS52176B (sr) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | Antitela visokog afiniteta prema humanom il-6 receptoru |
| EP2240204A1 (en) * | 2008-02-04 | 2010-10-20 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
| KR101747103B1 (ko) | 2009-06-26 | 2017-06-14 | 리제너론 파마슈티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
| GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| RS59077B1 (sr) * | 2014-03-11 | 2019-09-30 | Regeneron Pharma | Anti-egfrviii antitela i njihova primena |
| TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| CA2976446A1 (en) * | 2015-02-13 | 2016-08-18 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind ctla4 |
| SI3303394T1 (sl) * | 2015-05-29 | 2020-10-30 | Agenus Inc. | Protitelesa proti-CTLA-4 in postopki njihove uporabe |
| CN107406504B (zh) * | 2015-11-19 | 2021-04-30 | 蔡则玲 | Ctla-4抗体及其用途 |
| WO2018107178A1 (en) * | 2016-12-09 | 2018-06-14 | Regeneron Pharmaceuticals, Inc. | Systems and methods for sequencing t cell receptors and uses thereof |
| TWI799432B (zh) * | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
-
2018
- 2018-07-25 TW TW107125627A patent/TWI799432B/zh active
- 2018-07-26 JP JP2020503984A patent/JP7296363B2/ja active Active
- 2018-07-26 WO PCT/US2018/043936 patent/WO2019023482A1/en not_active Ceased
- 2018-07-26 MY MYPI2020000159A patent/MY202870A/en unknown
- 2018-07-26 AU AU2018307675A patent/AU2018307675B2/en active Active
- 2018-07-26 MA MA049687A patent/MA49687A/fr unknown
- 2018-07-26 KR KR1020207005683A patent/KR102710122B1/ko active Active
- 2018-07-26 EP EP18752992.0A patent/EP3658585A1/en active Pending
- 2018-07-26 IL IL271882A patent/IL271882B2/en unknown
- 2018-07-26 BR BR112020001266-1A patent/BR112020001266A2/pt unknown
- 2018-07-26 US US16/046,551 patent/US10844137B2/en active Active
- 2018-07-26 CN CN201880051789.XA patent/CN111133004B/zh active Active
- 2018-07-26 SG SG11202000366WA patent/SG11202000366WA/en unknown
-
2020
- 2020-01-08 ZA ZA2020/00113A patent/ZA202000113B/en unknown
- 2020-01-09 PH PH12020500078A patent/PH12020500078A1/en unknown
- 2020-01-15 CO CONC2020/0000438A patent/CO2020000438A2/es unknown
- 2020-01-24 CL CL2020000216A patent/CL2020000216A1/es unknown
- 2020-10-14 US US17/070,129 patent/US12024570B2/en active Active
-
2023
- 2023-06-09 JP JP2023095262A patent/JP2023113893A/ja active Pending
-
2024
- 2024-05-20 US US18/669,172 patent/US20250122307A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020528750A5 (enExample) | ||
| JP2023113893A5 (enExample) | ||
| JP2024037894A5 (enExample) | ||
| IL276830B1 (en) | Anti-claudin 18.2 antibodies and their uses | |
| RU2018145852A (ru) | Антитело против lag-3, его антигенсвязывающий фрагмент и их фармацевтическое применение | |
| JP2020534250A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| FI3932951T3 (fi) | Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| JP2017535257A5 (enExample) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| RU2016104880A (ru) | Способы лечения рака с использованием антагонистов, связывающих с осью pd-1, и ингибиторов tigit | |
| JP2019503361A (ja) | がんを治療するための抗ｐｄ−１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ | |
| RU2017118225A (ru) | Антитела к PD-1 и способы их применения | |
| RU2019104980A (ru) | Анти-icos антитела | |
| HRP20190749T1 (hr) | Ljudska antitijela na pd-l1 | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| JP2017512759A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| JP2020522281A5 (enExample) | ||
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| RU2017114968A (ru) | Связывающие молекулы, а именно антитела, способные связываться с l1cam (cd171) | |
| JP2021512652A5 (enExample) | ||
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| JPWO2021003357A5 (enExample) |